公开(公告)号：US20240366741A1

公开(公告)日：2024-11-07

申请号：US18550036

申请日：2022-03-08

Applicant: Purdue Research Foundation ,  HOUSTON METHODIST RESEARCH INSTITUTE

Inventor： Suresh Kumar Mittal ,  Chinnaswamy Jagannath

IPC: A61K39/04 ,  A61K39/00 ,  A61P31/06 ,  C12N15/86

Abstract: The present invention discloses a recombinant adenovirus vector of a replication-defective human adenovirus (HAdv85C5) or a bovine adenovirus (BAdv85C5) comprising a recombinant adenovirus vector having a heterologous DNA segment encoding mycobacterial Ag85B-p25 epitope (SEQ ID NO: 1), mycobacterial Ag85B-p25 epitope fusion of autophagy-inducing peptide-C5 (SEQ ID NO: 2), or a substantially homologous functional fragment thereof. The vector, having a heterologous DNA segment of SEQ ID NO: 3, SEQ ID NO: 4, or a substantially homologous functional fragment thereof, is an effective vaccine for therapeutically or prophylactically immunizing a subject for protection of infections by various microorganisms, especially Mycobacterium tuberculosis (Mtb), which causes the widespread tuberculosis. Methods of uses and pharmaceutical composition matters are within the scope of this disclosure.

公开(公告)号：US20230271024A1

公开(公告)日：2023-08-31

申请号：US18165916

申请日：2023-02-07

Applicant: THE METHODIST HOSPITAL DBA HOUSTON METHODIST HOSPITAL

Inventor： Santosh Anand Helekar ,  David Stuart Baskin ,  Martyn Alun Sharpe ,  Kumar Pichumani

IPC: A61N2/00 ,  A61N2/06 ,  A61N2/12

CPC classification number: A61N2/004 ,  A61N2/06 ,  A61N2/12

Abstract: To disrupt mitochondrial function in certain cells, controlling hardware causes a magnet to oscillate so as to generate an oscillating magnetic field. The oscillating magnetic field is applied to a volume of tissue including cells with degraded mitochondria to trigger apoptosis in the cells with degraded mitochondria.

公开(公告)号：US20220168322A1

公开(公告)日：2022-06-02

申请号：US17261536

申请日：2019-07-19

Applicant: Board of Regents, The University of Texas System ,  The Methodist Hospital dba Houston Methodist Hospital

Inventor： David John TWEARDY ,  Ren KONG ,  Uddalak BHARADWAJ ,  Moses Makokha KASEMBELI ,  Stephen T. C. WONG

IPC: A61K31/635 ,  A61K45/06 ,  A61K31/122 ,  A61K31/167 ,  A61K31/427 ,  A61K31/496 ,  A61K31/426 ,  A61K31/454 ,  A61P35/00

Abstract: In one aspect, the present disclosure provides methods of inhibiting STAT3 in a cell comprising contacting the cell with a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure provides methods of using of the compounds disclosed herein for the treatment of cancer.

公开(公告)号：US20210052563A1

公开(公告)日：2021-02-25

申请号：US16975257

申请日：2019-02-28

Applicant: Baylor College of Medicine ,  The Methodist Hospital d/b/a Houston Methodist

Inventor： Yohannes T. Ghebre ,  Michelle S. Ludwig ,  Mark David Bonnen ,  Pavan Mukesh Jhaveri

IPC: A61K31/4439 ,  A61K33/30 ,  A61K33/38 ,  A61K31/661 ,  A61K45/06 ,  A61K9/00 ,  A61P17/00

Abstract: Embodiments of the disclosure include methods and compositions related to treatment or prevention of cancer therapy-induced tissue inflammation, dermatitis, and/or scarring. In particular embodiments one or more proton pump inhibitors are provided to an individual before, during, and/or after receiving anticancer therapy. In some embodiments one or more proton pump inhibitors are provided to an individual before, during, and/or after having a health conditions, allergies, genetic factors and/or exposure to one or more irritants.

公开(公告)号：US20250135218A1

公开(公告)日：2025-05-01

申请号：US19012544

申请日：2025-01-07

Applicant: THE METHODIST HOSPITAL DBA HOUSTON METHODIST HOSPITAL

Inventor： Santosh Anand Helekar ,  David Stuart Baskin ,  Martyn Alun Sharpe ,  Kumar Pichumani

IPC: A61N2/00 ,  A61K31/19 ,  A61K31/20 ,  A61N2/12

Abstract: To disrupt mitochondrial function in certain cells, controlling hardware causes a magnet to oscillate so as to generate an oscillating magnetic field. The oscillating magnetic field is applied to a volume of tissue including cells with degraded mitochondria to trigger apoptosis in the cells with degraded mitochondria.

公开(公告)号：US20200222453A1

公开(公告)日：2020-07-16

申请号：US16608713

申请日：2018-04-30

Applicant: WILLIAM MARSH RICE UNIVERSITY ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  BAYLOR COLLEGE OF MEDICINE ,  HOUSTON METHODIST RESEARCH INSTITUTE ,  THE UNITED STATES GOVERNMENT

Inventor： James M. TOUR ,  Lizanne NILEWSKI ,  William SIKKEMA ,  Kimberly MENDOZA ,  Thomas Andrew KENT ,  William DALMEIDA, Jr. ,  Paul J. DERRY ,  Ah-Lim TSAI ,  Muralidhar L. HEGDE ,  Prakash DHARMALINGAM ,  Pavana Dixit HEGDE ,  Sankar MITRA ,  Joy MITRA

IPC: A61K33/36 ,  A61K9/51 ,  A61K9/16 ,  A61K33/24 ,  A61K33/34 ,  A61K33/26 ,  A61K33/241 ,  A61K33/04 ,  A61K33/30 ,  A61P25/28

Abstract: Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.

公开(公告)号：US20240050587A1

公开(公告)日：2024-02-15

申请号：US17766123

申请日：2020-10-01

Applicant: ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (I.R.S.T.) S.R.L. ,  HOUSTON METHODIST HOSPITAL

Inventor： Alessandro DE VITA ,  Chiara LIVERANI ,  Toni IBRAHIM ,  Laura MERCATALI ,  Ennio TASCIOTTI ,  Roberto MOLINARO

IPC: A61K47/69 ,  C07K16/40 ,  A61K31/704 ,  A61K47/68 ,  A61P35/00

CPC classification number: A61K47/6913 ,  C07K16/40 ,  A61K31/704 ,  A61K47/6855 ,  A61P35/00 ,  C12Y113/11

Abstract: The present invention relates to a liposome comprising a poly(ethylene glycol)-lipid (PEG-lipid), cholesterol and an anti-LOX antibody and relative pharmaceutical formulation, medical uses in particular for the treatment of cancer.

公开(公告)号：US20230181686A1

公开(公告)日：2023-06-15

申请号：US17999348

申请日：2021-06-21

Applicant: Baylor College of Medicine ,  The Methodist Hospital d/b/a Houston Methodist

Inventor： Yingbin Fu ,  Longhou Fang ,  Mackenzie Parker ,  Megan Shen ,  Qing Yan ,  Nduka Enemchukwu

IPC: A61K38/17 ,  A61P27/02

CPC classification number: A61K38/1709 ,  A61P27/02

Abstract: Embodiments of the disclosure include methods and compositions for the treatment of neovascularization- and ischemic retinopathy-related disorders. In some embodiments, a composition comprising an effective amount of an apoA-I binding protein or its agonist in combination with anti-VEGF reagents is administered to an individual in need thereof to treat, prevent, reverse, and/or meliorate conditions associated with macular degeneration or cancer. In some embodiments, a composition comprising an effective mount of an AIBP-inhibitor is administered to an individual in need thereof to stimulate revascularization in the eye to treat, prevent, reverse, and/or ameliorate conditions associated with ischemic retinopathies.

公开(公告)号：US20220193436A1

公开(公告)日：2022-06-23

申请号：US17567101

申请日：2021-12-31

Applicant: THE METHODIST HOSPITAL DBA HOUSTON METHODIST HOSPITAL

Inventor： Santosh Anand Helekar ,  David Stuart Baskin ,  Martyn Alun Sharpe ,  Kumar Pichumani

IPC: A61N2/00 ,  A61N2/06 ,  A61N2/12

Abstract: The disclosure provides methods of cancer treatment and apparatus and, more particularly, to non-invasive cancer treatments utilizing oscillating magnetic fields to disrupt mitochondrial function or induce apoptosis or another mechanism of cell death in cancer cells. The disclosure also provides a device for providing an OMF treatment to a subject.

公开(公告)号：US11071752B2

公开(公告)日：2021-07-27

申请号：US16385957

申请日：2019-04-16

Applicant: ABT Holding Company ,  Houston Methodist Hospital

Inventor： Saverio La Francesca ,  Anthony E. Ting ,  Robert J. Deans

IPC: A61K35/12 ,  C12N5/074 ,  C12N5/00

Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.